Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This intervention is a combination therapy consisting of the surgical procedure core decompression and the implantation of autologous bone marrow concentrate (BMC). Core decompression is a standard surgical technique used to reduce intraosseous pressure and promote revascularization in early-stage avascular necrosis (osteonecrosis) of the femoral head. BMC is a biological product obtained by harvesting the patient's own bone marrow (typically from the iliac crest) and concentrating the mononuclear cell fraction, which includes mesenchymal stem cells (MSCs), hematopoietic stem cells, and various growth factors, via density gradient centrifugation. The goal of combining BMC with core decompression is to provide a concentrated source of osteogenic progenitor cells to enhance bone repair and regeneration within the necrotic lesion. In clinical trials conducted at Erasme University Hospital, this procedure served as the active control arm for evaluating the efficacy of PREOB®, an ex vivo expanded autologous osteoblastic cell therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bone marrow concentrate + core decompression.